Table 5. HIV-RNA and CD4 values and estimated CD4 slope during elite control (EC), and throughout ART-naïve follow-up using the CASCADE dataset applied to 10 definitions of EC found in the literature.
| Def. | During Elite Control | During ART-naïve follow-up | ||||
| HIV-RNA value | CD4 Value | CD4 slope † (95% CI) | HIV-RNA value | CD4 Value | CD4 slope † (95% CI) | |
| Aŧ | 50 (35, 276) | 675 (454, 877) | 0.04 (0.01, 0.08) | 66 (35, 495) | 654 (441, 840) | −0.09 (−0.12, −0.06)‡ |
| Bŧ | 425 (35, 11641) | 573 (409, 792) | −0.16 (−0.19, −0.12)‡ | 1043 (89, 13000) | 548 (404, 751) | −0.28 (−0.30, −0.25)‡ |
| Cŧ | 354 (50, 8700) | 596 (427, 796) | −0.18 (−0.21, −0.15)‡ | 660 (75, 11066) | 567 (415, 764) | −0.31 (−0.34, −0.29)‡ |
| Dŧ | 903 (287, 1863) | 615 (478, 789) | −0.27 (−0.29, −0.25)‡ | 1274 (370, 3304) | 590 (451, 756) | −0.43 (−0.45, −0.41)‡ |
| Eŧ | 50 (35, 81) | 699 (528, 922) | 0.06 (0.01, 0.10) | 50 (35, 165) | 681 (527, 909) | −0.06 (−0.10, −0.02) |
| Fŧ | 50 (35, 50) | 839 (654, 1070) | 0.05 (−0.00, 0.11) | 50 (35, 77) | 796 (629, 1020) | −0.08 (−0.13, −0.03) |
| Gŧ | 113 (49, 1197) | 644 (439, 824) | −0.06 (−0.09, −0.03)‡ | 176 (50, 2160) | 625 (438, 806) | −0.15 (−0.18, −0.13)‡ |
| Hŧ | 76 (35, 283) | 697 (541, 879) | −0.09 (−0.12, −0.05)‡ | 89 (35, 356) | 687 (530, 879) | −0.23 (−0.26, −0.20)‡ |
| Iŧ | 35 (1, 35) | 583 (575, 905) | −0.07 (−0.24, 0.09) | 35 (1, 35) | 583 (575, 905) | −0.05 (−0.21, 0.11) |
| Jŧ | 50 (35, 127) | 783 (628, 970) | −0.03 (−0.09, 0.02) | 50 (35, 169) | 740 (583, 970) | −0.11 (−0.16, −0.06)‡ |
Note- all values unless otherwise stated are median (IQR).
CD4 slope modelled on the square root scale with linear mixed models, specific p-values for CD4 slope and median number of CD4 measurements are presented in Table S1.
CD4 slope highly significant p<0.001.
Ŧ Number of total CD4 and HIV-RNA measurements ŧ A: HIV-positive ≥6 months, with ≥2 consecutive HIV-RNA <75 copies/ml; B: HIV- positive ≥1 year, with ≥1 HIV-RNA <50 copies/ml, C: HIV- positive ≥1 year, with ≥1 HIV-RNA <75 copies/ml, D: HIV- positive ≥1 year, with ≥3 HIV-RNA <2000 copies/ml, E: HIV- positive ≥1 year, with ≥3 consecutive HIV-RNA <75 copies/ml spanning ≥12 months F: HIV- positive ≥1 year, with ≥3 consecutive HIV-RNA <75 copies/ml spanning ≥12 months with no previous blips ≥1000 copies/ml, G:HIV- positive ≥2 years, with ≥2 HIV-RNA <75 copies/ml, H: HIV- positive ≥5 years, with ≥5 consecutive HIV-RNA <500 copies/ml, I: HIV- positive ≥10 years, with all measured HIV-RNA <50 copies/ml, J: HIV-positive ≥10 years, with ≥90% of HIV-RNA (≥2 HIV-RNA ever) <400 copies/ml.